Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Anticancer activity of okra raw polysaccharides extracts against human liver cancer cells

Suhailah Hayaza1, Sri Puji Astuti Wahyuningsih1, Raden Joko Kuncoroningrat Susilo1, Adita Ayu Permanasari1, Saikhu Akhmad Husen1, Dwi Winarni1, Hunsa Punnapayak1,2, Win Darmanto1

1Department of Biology, Faculty of Science and Technology Universitas Airlangga, Kampus C Universitas Airlangga, Surabaya 60115, Indonesia; 2Plant Biomass Utilization Research Unit, Department of Botany, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.

For correspondence:-  Win Darmanto   Email: windarmanto@fst.unair.ac.id   Tel:+62315936501

Accepted: 24 July 2019        Published: 28 August 2019

Citation: Hayaza S, Wahyuningsih SP, Susilo RJ, Permanasari AA, Husen SA, Winarni D, et al. Anticancer activity of okra raw polysaccharides extracts against human liver cancer cells. Trop J Pharm Res 2019; 18(8):1667-1672 doi: 10.4314/tjpr.v18i8.15

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To examine raw polysaccharides extract of okra (Abelmoschus esculentus L.) as an anticancer agent against human liver cancer cells.
Methods: Okra raw polysaccharide extract (ORPE) was obtained by ethanol extraction from the raw fruit. Huh7it cells were grown in DMEM (Dulbecco's Modified Eagle Medium) and cultured for 24 h prior to treatment with the extract. The cell culture was divided into 3 groups, viz, negative control group (KN), positive control group (KP, treated with 10 μg/mL doxorubicin), and ORPE (P) group. ORPE group was divided into 5 subgroups based on the dose used for treatment, viz, 50 (P1), 100 (P2), 200 (P3), 400 (P4), and 600 µg/mL (P5). Huh7it cell proliferation was measured by MTT assay. while measurement of Huh7it cell apoptosis, necrosis, and cell cycle analysis were carried out using Annexin V FITC-PI antibody test and flow cytometry.
Results: ORPE significantly inhibited Huh7it cell proliferation and induced apoptosis. ORPE treatment with 600 µg/mL extract caused 5.82 % late cell apoptosis and 5.62 % early apoptosis. Cell cycle arrest occurred during G0/G1 phase.
Conclusion: ORPE is a potential anticancer agent against human liver cancer cells due to its ability to induce apoptosis of huh7it cells by promoting cell cycle arrest during G0/G1 phase.

Keywords: Abelmoschus esculentus L., Anticancer, Apoptosis, Cell cycle, Cell proliferation, Liver cancer, Raw okra polysaccharides

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates